NetraMark
Healthcare Software · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1655 Dupont St Suite 101, Toronto, Ontar...Phone Number
(403) 681-2549Website
www.netramark.comRevenue
<$5 MillionStock Symbol
AIAIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About NetraMark
NetraMark specializes in advanced AI solutions designed to enhance clinical trial development processes. Their flagship product, NetraAI, utilizes innovative technology to provide insights into patient populations, optimizing study design and improving trial efficacy. The company also offers solutions like NetraPlacebo and NetraGPT, which leverage data to understand placebo responses and enhance explainability, respectively. Target clients include clinical trial professionals and sponsors looking to improve trial outcomes through data-driven insights.Explore more
NetraMark Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NetraMark your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NetraMark is spiking on competitors!
Earning: See what the market has to say on NetraMark recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NetraMark launches new products
NetraMark, which may be a good buyer, showed buying intent in Masked Content Topic
Check if NetraMark has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NetraMark has new funding data
Website visits: Recent activity has been detected on your website
Click to see if NetraMark had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NetraMark
Recommended Actions
Find VP level buyers at NetraMark
Find more new buyers
Compare Similar Companies to NetraMark
Compare insights from companies similar to NetraMark, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NetraMark is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
NetraMark is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about NetraMark.
NetraMark financials insights
Gather financial insights about NetraMark, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$2.5M
NetraMark Tech Stack
A closer look at the technologies used by NetraMark
See more technologies
Most Recent Scoops
Event
Events
Person-Based
Business Development
Person-Based
Contracts
Person-Based
Clinical Operations, Communications, Marketing Communications
Person-Based
Clinical Operations, Public Relations
NetraMark News & Media
NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor
TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strategic and institutional experience surrounding the Company as NetraMark advances its commercialization strategy.NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and Abivax Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and AbivaxNetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High
Company highlights growing contracted project activity, expanding pharmaceutical engagements, initial commercial activation of CRO channel and continued scientific progress Company highlights growing contracted project activity, expanding pharmaceutical engagements, initial commercial activation of CRO channel and continued scientific progress
Read more news
Top Healthcare Software Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding NetraMark
Sign Up For FreeTo access detailed company insights
NetraMark specializes in advanced AI solutions designed to enhance clinical trial development processes. Their flagship product, NetraAI, utilizes innovative technology to provide insights into patient populations, optimizing study design and improving trial efficacy. The company also offers solutions like NetraPlacebo and NetraGPT, which leverage... Read More
